



Biosergen publishes interim report for first quarter 2023

Monday, August 14, 2023: Biosergen AB ("Biosergen" or the "Company") thereby publishes the interim report for the second quarter 2023. The interim report is available as an attached document and on the company website (www.biosergen.net)

Summary of the Interim Report for Q2 2023

TSEK	2023 April-June	2022 April-June	2023 Jan-June	2022 Jan-June	2022 Jan-Dec
Profit/loss					
Other income	2.456	1.409	7.771	2.726	5.183
Profit/loss before depreciation (EBITDA)	-8.038	-7.963	-13.067	-12.981	-34.129
Operating profit/loss before net financials	-8.038	-7.963	-13.067	-12.981	-34.129
Net financials	7	3	9	6	81
Netprofit/loss for the period	-8.031	-7.960	-13.058	-12.975	-34.048
Earnings per share (SEK)	-0,19	-0,28	-0,31	-0,46	-1,09

Highlights during Q2 2023

- March 29, Biosergen provides Phase 2 clinical development strategy update.

Highlights after the period

- August 7, Biosergen Announces Abstract Accepted for Presentation at the 11th Congress on Trends in Medical Mycology (TIMM-11)

The Financial report can be found on our website: <http://biosergen.net/investors/filings>

For further information about Biosergen, please contact:

Dr. Peder M. Andersen, CEO

Telephone: +45 2080 2470

E-mail: peder.andersen@biosergen.net

Niels Laursen, CFO

Telephone: +45 4014 5059

Email: niels.laursen@biosergen.net

Certified Adviser

Erik Penser Bank

Telefon: +46 8 463 8000

E-mail: certifiedadvisor@penser.se

ABOUT BIOSERGEN

Biosergen is a leading clinical-stage biotechnology company at the forefront of antifungal drug development. Our mission is to develop BSG005, our lead drug candidate, into the new first-line treatment choice for invasive fungal diseases, while generating significant returns for our shareholders. Our Phase I trial showcased the exceptional safety and tolerability of BSG005, especially when compared to existing alternatives. Building on those results we are now advancing to Phase II clinical trials expected to clinically validate BSG005's potential as a game-changing antifungal treatment. Biosergen's development of BSG005 is based on two decades of scientific work at the Norwegian University of Science and Technology. For more information, visit www.biosergen.net.